Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?
1. PTCT's Phase 2 study met primary endpoint for Huntington's disease treatment. 2. Blood HTT levels decreased significantly, indicating a potential disease-modifying therapy. 3. Investors reacted negatively, causing an 18.6% drop in PTCT stock price. 4. Safety profile shows no serious adverse events or neurofilament spikes. 5. Next steps may include discussions on accelerated approval for PTC518.